George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksLID.L Regulatory News (LID)

  • There is currently no data for LID

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.3 - LiDCO Group Plc

6 Nov 2020 16:22

RNS Number : 5689E
LiDCO Group Plc
06 November 2020
 

FORM 8.3

 

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Full name of discloser:

Horace Joseph Leitch

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

Horace Joseph Leitch

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

LiDCO Group Plc

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

(e) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

Opening Position

04.11.2020

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

N/A

 

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

 

Class of relevant security:

 

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

 

16,806,183

 

6.88

(2) Cash-settled derivatives:

 

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

 

TOTAL:

 

16,806,183

 

6.88

 

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

(b) Rights to subscribe for new securities (including directors' and other employee options)

 

Class of relevant security in relation to which subscription right exists:

Details, including nature of the rights concerned and relevant percentages:

 

 

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchase/sale

 

Number of securities

Price per unit

 

 

 

(b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

None

 

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

None

 

 

 

(c) Attachments

 

Is a Supplemental Form 8 (Open Positions) attached?

NO

 

 

Date of disclosure:

06.11.2020

Contact name:

Giles Cumner

Telephone number*:

01481 750 795

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

 

*If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel's Market Surveillance Unit.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RETUNRNRRSUARAA
Date   Source Headline
1st May 20147:00 amRNSPositive haemodynamic monitoring study
29th Apr 20147:00 amRNSFinal Results
7th Apr 20147:00 amRNSNotice of Results and Investor briefing
17th Mar 20147:00 amRNSLaunch of New Version of LiDCOrapid software
12th Mar 20147:00 amRNSResults of cost effectiveness trial
28th Feb 201411:34 amRNSTotal Voting Rights
12th Feb 20147:00 amRNSTrading update and notice of results
7th Feb 20149:21 amRNSHolding(s) in Company
28th Jan 20143:01 pmRNSHolding(s) in Company
27th Jan 20144:10 pmRNSBlocklisting Application
20th Jan 20149:54 amRNSReplacement:Anaesthetists guidelines supports LID
20th Jan 20147:00 amRNSAnaesthetists guidelines supports LiDCO
18th Oct 20134:04 pmRNSExercise of Share Options
1st Oct 20137:00 amRNSHalf Yearly Report
26th Sep 20137:00 amRNSNotice of Patent Acceptance
20th Sep 20137:00 amRNSInvestor Results Briefing
6th Sep 20134:33 pmRNSHolding(s) in Company
4th Sep 20137:00 amRNSFDA clearance
20th Aug 20137:00 amRNSTrading update
13th Aug 201312:11 pmRNSNotification of major interest in shares
12th Jun 201311:43 amRNSResults of Annual General Meeting
12th Jun 20137:00 amRNSAGM Statement
10th Jun 201310:08 amRNSNotification of major interest in shares
5th Jun 20137:00 amRNSLiDCOrapid in successful recovery programme
31st May 20139:50 amRNSGrant of Share Options
17th May 20133:30 pmRNSNotice of AGM and posting of Annual Report
9th May 20137:00 amRNSLiDCOrapidv2 incorporated in NHS Foundation Trust
8th May 20133:51 pmRNSExercise of Share Options
23rd Apr 20137:00 amRNSPreliminary Results
26th Mar 20137:00 amRNSUS FDA clears for sale LiDCOrapidv2
15th Mar 20137:00 amRNSGrant of LiDCOrapid user interface patent in Japan
22nd Feb 20133:25 pmRNSDirector/PDMR Shareholding
21st Feb 201312:45 pmRNSExercise of Share Options
7th Feb 20137:03 amRNSLaunch and first sales of the LiDCOrapid v2
5th Feb 20137:00 amRNSTrading Update and Notice of Preliminary Results
17th Dec 20127:00 amRNSTrading Statement
29th Nov 20122:00 pmRNSTR-1 Notification of Major Interest in Shares
27th Nov 20127:00 amRNSExercise of Share Options
27th Nov 20127:00 amRNSProtocol using LiDCOrapid improves outcomes
23rd Nov 20127:00 amRNSLiDCOrapid v2 satisfies NICE recommendation
13th Nov 20127:00 amRNSFundraising to raise £2.35 million
23rd Oct 20127:00 amRNSInterim Results
15th Oct 20123:00 pmRNSExercise of Share Options
15th Oct 20127:00 amRNSPremier of LiDCOrapid v2 with Unity Software
14th Sep 20123:20 pmRNSNotice of Interim Results
3rd Sep 201212:00 pmRNSExercise of Share Options
23rd Aug 20127:00 amRNSTrading update and resignation of Director
3rd Aug 20127:00 amRNSNihon Kohden appointed as distributor in Japan
11th Jul 20127:00 amRNSReimbursement approval received in Japan
4th Jul 20123:05 pmRNSGrant of Share Option

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.